Is Pyxis Oncology Inc (PYXS) overvalued? · rev $2.8M
Pyxis Oncology Inc (PYXS) is a biotechnology company listed on NASDAQ.
This page asks whether Pyxis Oncology Inc (PYXS) looks expensive on cached numbers — not a short thesis.
Latest reported PYXS revenue for 2025-09-30 was $2.8M. Net income was -$22.0M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. PYXS currently screens at market cap $109.6M.
PYXS currently screens at market cap $109.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PYXS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PYXS stock page for the full model, not this heading.
Not investment advice.